Every oncologist has a dream – doing more with less toxicity. Targeted therapies seem to be the key for an oncologist’s dreams by defining subgroups of those patients who benefit more from a specific treatment and those who do not. For a few years now, targeted therapies have played a major role in the treatment of primary as well as metastatic breast cancer. In this article, we describe targeted therapies that already play an important role in clinical decisions in the treatment of metastatic as well as primary breast cancer. The humanised monoclonal antibody trastuzumab is a very effective agent in primary and metastatic breast cancer, but only for those patients whose tumours are overexpressing HER2/neu. Bevacizumab is an antibody directed against vascular epidermal growth factor ligand A which plays a role in angiogenesis. Up to now there is no predictive factor known for this treatment. Furthermore, we would like to give an impression of new agents and strategies under investigation like tyrosine kinase inhibitors and other small molecules.

Keywords:
Breast cancer, Targeted therapies, Epidermal growth factor receptors, Vascular epidermal growth factors
This content is only available via PDF.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.